Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication ...

I remain bullish on Eli Lilly’s long-term growth prospects and expect the company will be able to meet or exceed long-term expectations, but relative valuations are now less favorable than they ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently ...

As a result, the company gains more resources to boost innovation and still maintain EBITDA growth. Eli Lilly's growth strategy is multi-layered, a mix of in-house innovation and acquisitions and ...

Like Leqembi, Lilly's Kisunla is designed to clear an Alzheimer ... patients experiencing potentially serious brain swelling, the company said. Additionally, unlike Leqembi, Kisunla has finite ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a splash in the weight loss space thanks to its one-two punch of blockbuster ...

See Correction/Clarification at the end of this article. Eli Lilly is the maker of high-in-demand injectable pharmaceuticals like Mounjaro, used for the treatment of diabetes and weight loss.